Pangaea Data

Cambridge-based AI healthcare scale-up Pangaea Data is actively seeking a £75 million financing round to capitalize on surging global demand for its clinical intelligence software, which mines unstructured electronic health records to identify undiagnosed and underserved patient populations.

Company Profile & Platform Overview

Pangaea Data is an enterprise AI and deep tech company headquartered in Cambridge, United Kingdom, with a specialized focus on healthcare and life sciences. The company has developed a proprietary, patented unsupervised AI and natural language processing (NLP) engine designed to extract critical insights from unstructured electronic health records (EHRs) and clinical narratives. Unlike traditional analytics tools that rely heavily on structured billing codes—which frequently miss up to 50% of patient cohorts—Pangaea's technology reads clinician notes with high precision, identifying hard-to-diagnose conditions and matching eligible patients for complex clinical trials.

The company's enterprise software-as-a-service (SaaS) business model targets tier-one global pharmaceutical companies, contract research organizations (CROs), and major healthcare providers. By deploying its secure, privacy-compliant AI pipelines within hospital systems and pharma R&D divisions, Pangaea significantly compresses the timeline for patient recruitment while generating high-margin recurring software revenues. The core product moat stems from its proprietary clinical ontologies, domain-specific language models, and deep integration into secure hospital workflows, establishing high switching costs and robust barriers to entry against generic large language model providers.

Positioned at the intersection of enterprise AI and life sciences, Pangaea Data represents the maturation of UK academic spin-out technology into a globally scalable commercial engine. With rising demand for clinical efficiency and precision medicine, the company's dual focus on accelerating drug development and improving real-world diagnostic yields has positioned it as a bellwether for the resilience and long-term viability of the British deep tech ecosystem.